nPulse AF System Shows 90% Freedom from Atrial Fibrillation at 12 Months
Summary
Pulse Biosciences announced highly positive 12-month clinical data for its nPulse Cardiac Catheter System, demonstrating a 90% Kaplan-Meier estimate of freedom from AF/AFL/AT and a low serious adverse event rate of 1.7%. This robust data builds upon previous positive clinical updates, providing more specific and longer-term efficacy and safety metrics for a pivotal product. These strong results are a significant de-risking event for the company's lead therapeutic candidate, potentially enhancing its regulatory and commercial outlook. Investors will now focus on the company's next steps towards regulatory submissions and further clinical milestones.
At the time of this announcement, PLSE was trading at $23.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $12.56 to $26.30. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.